Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Invasive Candidiasis
Mucocutaneous Candidiasis
Coccidioidomycosis
Histoplasmosis
Blastomycosis
Chronic Pulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis
Invasive Pulmonary Aspergillosis
Recurrent Vulvovaginal Candidiasis
Other Emerging Fungi

Interventions

DRUG: Ibrexafungerp

Sponsor

Scynexis, Inc.